More biosimilar use could've saved Medicare and beneficiaries $84M in 2019, HHS OIG says
In the nearly 7 years since biosimilars were first approved in the US, the story has been one of lackluster uptake, amid a growing familiarity with the way the patent “dance” works, and how the FDA approval process plays out.
But the biosimilar side of the biologics equation is going to need to carry more of the weight moving forward as biologics are estimated to cost CMS’ Part D program upwards of $12 billion annually, and that number has been going up in recent years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
